Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 2,258 shares at $54.84 ($124K) on 2025-06-18, disclosed to the SEC on 2025-06-20.
Open-market sale of $124k AKRO by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.84 | 1,129 | $62K | 50.0% |
| 2 | $54.84 | 1,129 | $62K | 50.0% |
| Total | $54.84 avg | 2,258 | $124K | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |